Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiankui Congying Granules (天癸苁盈颗粒) is an innovative Traditional Chinese Medicine (TCM) candidate classified as a Class 1.1 drug, currently under development by Monyan Pharmaceutical. The drug is formulated as an oral granule specifically for the treatment of menopausal syndrome (perimenopausal syndrome). In TCM theory, "Tiankui" refers to the vital substance responsible for reproductive and developmental functions, which naturally declines during the menopausal transition. This formulation is designed to address the systemic imbalances and symptoms associated with this decline. As a Class 1.1 TCM, it represents a new herbal combination or a significantly modified traditional formula with demonstrated clinical potential. It is currently in Phase 2 clinical trials in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tiankui Congying Granules.